Appendix B

Biographical Sketches of the Workshop Planning Committee, Speakers, and Panelists

PLANNING COMMITTEE BIOSKETCHES

Cherié Butts, Ph.D., (co-chair) joined Biogen in 2012 and is currently its medical director of research and development. She was the clinical lead for peginterferon beta-1a (approved for multiple sclerosis in the European Union in 2020 and in the United States in 2021) and completed a health equity assignment focused on addressing gaps in clinical data to empower patients to make more informed treatment decisions. She earned B.A. and M.S. degrees from The Johns Hopkins University; received a Ph.D. from University of Texas MD Anderson Cancer Center; and completed a postdoctoral fellowship at the National Institutes of Health studying neuroendocrine regulation of immune cells. Prior to Biogen, she worked at the U.S. Food and Drug Administration, where she conducted research and evaluated new drug/biologics applications as immunogenicity and chemistry-manufacturing-controls reviewer. Dr. Butts is passionate about connecting research across academia, government, and industry to advance the biomedical ecosystem. She holds leadership positions in several local, national, and international organizations. This includes the Board of Celebrity Series of Boston, the board (as treasurer) of the Federation of American Societies for Experimental Biology (FASEB), the trustee advisory board of Beth Israel Deaconess Medical Center, the board of directors of Keystone Symposia, the board of trustees (chair) of Salem State University, the scientific advisory board of the Chan Zuckerberg Initiative, and educator (as adjunct professor) at University of Maryland.

Jonathan Watanabe, Pharm.D., Ph.D., BCGP, (co-chair) is a board-certified geriatrics pharmacist, health economist, and outcomes researcher. He is the associate dean of assessment and quality at the University of California, Irvine, School of Pharmacy & Pharmaceutical Sciences and serves as the director of the Center for Data-Driven Drugs Research and Policy. He serves as a member of the National Academies of Sciences, Engineering, and Medicine (NASEM) Forum on Drug, Discovery, Development, and Translation. Professor Watanabe has been involved in methods development for pragmatic clinical trials for the NASEM Real-World Evidence Workshop Series and served on the steering committee for the Drug Research Development in Older Adults Workshop. Dr. Watanabe applies real-world data to develop policy solutions to improve patient care, bolster population health, enhance access and equity for marginalized populations, and reduce medical costs applying data sourced from sources that include clinical trials, electronic health records, population surveys, and administrative claims. He has also conducted published research on the clinical work force. He is a past National Academy of Medicine (NAM) Anniversary Fellow in Pharmacy. He served as a scholar in the NAM Emerging Leaders in Health and Medicine Program. Dr. Watanabe’s research on health implications of non-optimized medication regimens has been cited in legislative efforts to bolster patient-centered care and medication management. He is appointed to the Task Force of the California Health Benefits Review Program of the California State Legislature and served on the Advisory Group on Pain Assessment and Management in Long-Term Care Settings for the Joint Commissions. He has been involved in national quality metrics development on long-term care and transitions of care with prior service on the Pharmacy Quality Alliance. He has previously served on the American Academy of Neurology Neurotherapies Workgroup on Pharmacoeconomics. He received his B.S. from the University of Washington, his Pharm.D. from the University of Southern California, and his M.S. and Ph.D. from the University of Washington Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. He has prior direct-patient care clinical experience at the Medicare-Medicaid Program of All-Inclusive Care for the Elderly (PACE) program, assisted living, skilled nursing, and long-term care settings.

Olujimi Ajijola, MD, Ph.D., completed his undergraduate studies at the University of Virginia and received his medical degree from Duke University. He went on to the Massachusetts General Hospital for residency training in internal medicine and completed clinical fellowships in cardiovascular medicine and cardiac electrophysiology at the University of California, Los Angeles (UCLA). He received a Ph.D. in molecular,

cellular, and integrative physiology at UCLA as part of the Specialty Training and Advanced Research (STAR) program. He is interested in novel approaches for cardiac arrhythmias and performs invasive cardiac electrophysiological procedures. His research interests revolve around peripheral neural circuits that control cardiac function in health and disease, including neural interventions that alleviate progressive cardiac dysfunction and arrhythmias. In addition to the National Institutes of Health (NIH) Director’s New Innovator award, he is a recipient of the Jeremiah Stamler Cardiovascular Research Award, an A. P. Giannini Foundation post-doctoral award, and a Young Physician Scientist Award from the American Society for Clinical Investigation (ASCI). He is a member of the New Voices program of the National Academies of Science, Engineering, and Medicine. He is a recipient of the Chan Zuckerberg Science Diversity Leadership Award and an elected member of the ASCI. He is the associate director of the UCLA Cardiac Arrhythmia Center and EP Programs and directs the Neurocardiology Research Program at UCLA. He also co-directs the NIH-funded UCLA–California Institute of Technology Medical Scientist Training Program.

Dowin Boatright, M.B.A., M.D., M.H.S., is the vice chair of research for the department of emergency medicine at the New York University Grossman School of Medicine. Previously, he had a fellowship as a Robert Wood Johnson Foundation Clinical Scholar at the Yale School of Medicine. Prior to this, he completed his residency in emergency medicine at Denver Health/University of Colorado where he also served as chief resident and among many honors received the Denver Health Program Director’s Award in 2015. Dr. Boatright’s research interests include diversity in the health care workforce and bias and discrimination in medical education. His work has been funded by the National Institute on Minority Health and Health Disparities and by the National Institute of General Medical Sciences. He is also board certified by the American Board of Emergency Medicine. Dr. Boatright is a graduate of Morehouse College, receiving his medical degree from Baylor College of Medicine, and a Master in Business Administration from Rice University.

Tammy Collins, Ph.D., joined the Burroughs Wellcome Fund (BWF) in the fall of 2022. At BWF, Dr. Collins serves as a program officer where she directs the Career Awards at the Scientific Interface (CASI) program and the Innovations in Regulatory Science Awards (IRSA). Prior to joining BWF, Dr. Tammy Collins was the director of the Office of Fellows’ Career Development at the National Institutes of Health–National Institute of Environmental Health Sciences (NIH–NIEHS). In this role, Dr. Collins provided professional development training to prepare postdoc-

toral scholars for the workforce and was focused on making their career outcomes transparent. To this end, she published research on NIEHS postdoctoral scholar outcomes in Nature Biotechnology and led a national effort for the Graduate Career Consortium to review career outcome classification and visualization methodologies in North America. She received an NIH Director’s Award for these efforts. Dr. Collins obtained her bachelor’s in chemistry from Appalachian State University (ASU), where she became ASU’s first Goldwater Scholar, and her Ph.D. in biochemistry from Duke University. After a brief postdoc at Duke, she joined NIEHS as a postdoc in 2009 where she developed her passion for helping foster scientific leaders.

Lola Fashoyin-Aje, M.D., M.P.H., is a medical oncologist and deputy director in the Division of Oncology 3 (DO3) in the Office of Oncologic Diseases at the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). In this role, she provides clinical, scientific, and regulatory policy guidance and oversight to multidisciplinary teams reviewing drugs and biologics under development for the treatment of solid tumor malignancies. Dr. Fashoyin-Aje is also an associate director in the FDA Oncology Center of Excellence (OCE) where she leads initiatives to address clinical and regulatory science and policy issues impacting oncology drug development. One such initiative is Project Equity, a public health initiative established to ensure that the data submitted to the FDA for approval of oncology medical products adequately reflect the demographic representation of patients for whom the medical products are intended. (https://www.fda.gov/about-fda/oncology-center-excellence/project-equity). Prior to joining the FDA, Dr. Fashoyin-Aje completed her undergraduate and graduate training at Columbia University and Yale University, respectively, and received her M.D. degree from the University of Rochester School of Medicine and Dentistry. She completed postgraduate training in internal medicine and medical oncology at Johns Hopkins.

Marcus Hodges, Ph.D., is the lead of intramural trainee development for the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS), where he develops, markets, implements and evaluates training and professional development activities for DPI intramural trainees. Serving as an advocate for NCATS fellows, Dr. Hodges ensures that trainees have opportunities to acquire and enhance the skills needed to succeed in a preclinical, translational science environment. Prior to joining NCATS, he served as the fellowship director for the National Biosafety and Biocontainment Training Program (NBBTP), overseeing the planning, coordination, and execution

of all didactic and experiential training for fellows. Dr. Hodges helped enhance the training curriculum and established developmental assignment partnerships with more than 25 government, academic and private-sector institutions. Dr. Hodges received his doctorate in biology from Howard University in Washington, D.C.. He then joined the Laboratory of Allergic Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) as a postdoctoral fellow and later completed a second postdoctoral fellowship, specializing in biological safety and biocontainment. Dr. Hodges aspires to increase awareness of translational science in populations that are underrepresented among biomedical scientists. Furthermore, he seeks to identify and apply strategies to recruit and retain people from these underrepresented populations for DPI training programs.

Heather Pierce, J.D., M.P.H., is the senior director for science policy and regulatory counsel at the Association of American Medical Colleges (AAMC). In this role, she serves as AAMC’s staff leader for scientific regulatory issues including clinical research, conflicts of interest, evidence-based regulation, and collaborations between industry, government, and academia in biomedical research. She is also the designated subject matter expert for the AAMC Forum on Conflict of Interest in Academe and for Convey, the AAMC’s global financial interest disclosure system. Ms. Pierce is a former Chair of the Board of Directors of Public Responsibility in Medicine and Research (PRIM&R), the Vice Chair of the Board of Directors for the Association for Accreditation of Human Research Protection Programs (AAHRPP) and regularly speaks at national forums on issues related to the protection of human subjects, conflicts of interest, scientific misconduct, and the regulation of research. She has served on ad hoc committees and task forces convened by organizations including the National Academies, The Pew Charitable Trusts, the National Dialogue on Healthcare Innovation, and PRIM&R. Prior to joining AAMC, Ms. Pierce was an attorney in the Health Care Group of the law firm of Ropes & Gray LLP in New York. Her regulatory practice focused on medical research and clinical care. She received her law degree from NYU School of Law and her M.P.H. in health law from Boston University.

Damani Piggott, M.D., Ph.D., is an associate professor in the Division of Infectious Diseases and the Department of Epidemiology and the associate vice provost for graduate diversity and partnerships at Johns Hopkins University. Dr. Piggott directs the Vivien Thomas Scholars Initiative, a $150 million effort supported by Bloomberg Philanthropies directed at connecting students from historically Black colleges and universities and minority-serving institutions to science, technology, engineering, and

mathematics (STEM) graduate education and future STEM leadership. Dr. Piggott has worked on clinical and research projects in urban and rural communities in the United States, the Caribbean, West Africa, and South Africa. His research centers on understanding the biological, behavioral, and social determinant pathways necessary to improve survival and quality of life for persons aging with HIV. Dr. Piggott received his bachelor of science degree in biology and Spanish from Morehouse College. He obtained his Ph.D. degree in immunology and his medical degree from Yale University. He completed residency training in internal medicine and pediatrics at Yale New Haven Hospital and fellowship training in infectious diseases and epidemiology at Johns Hopkins. Dr. Piggott is a fellow of the Infectious Diseases Society of America.

Amir Tamiz, Ph.D., is the director of the Division of Translational Research (DTR) at the National Institute of Neurological Disorders and Stroke (NINDS). DTR provides funding and resources (approximately $200 million annually) through grants, cooperative agreements, and contracts to academic and industry researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Dr. Tamiz has oversight for many flagship programs within NINDS and the National Institutes of Health (NIH) including the NIH Blueprint Neurotherapeutics Network (BPN) and Blueprint MedTech programs, NIH Helping to End Addiction Long-Term (HEAL) Preclinical Screening Platform (PSPP) and Pain Therapeutics Development Program (PTDP), NINDS Small Business Program, Office of Neural Exposome and Toxicology (ONETOX), NINDS Biomarker Program, Innovation Grants to Nurture Initial Translational Efforts (IGNITE), and NINDS Epilepsy Therapy Screening Program (ETSP). Prior to joining NIH in 2012, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer), and Alba Therapeutics.

Pamela Tenaerts, M.B.A., M.D., is the chief scientific officer at Medable, Inc. Dr. Tenaerts leads the scientific office at Medable to drive responsible advancement of decentralized research methodologies with evidence-based metrics and best practices. Dr. Tenaerts joined Medable from Duke, where she led the Clinical Trials Transformation Initiative’s efforts to develop and drive adoption of practices that increase the quality and efficiency of clinical trials. She is one of the leading advocates for innovation in clinical trials, with an emphasis on patient engagement, responsible evidence generation, and clinical trial methodology improvements. With more than 30 years’ experience in the conduct of clinical trials across a

number of stakeholders, she practiced medicine both in the emergency department and as a family practitioner in the private practice setting for several years before embarking on a career in research. She received her M.D. from Catholic University of Leuven, Belgium, and an M.B.A. from the University of South Florida. She speaks five languages and has obtained Six Sigma Green Belt certifications.

Lamont Terrell, Ph.D., is currently the diversity, equity, and inclusion (DEI) lead for the R&D organization. He is responsible for developing and implementing the DEI strategy for the global business. Prior to his pivot into leading human resource efforts to shape the R&D organization, he spent 14 years as a medicinal chemist leading projects in early drug discovery. As the DEI lead for R&D, one of his responsibilities is developing talent pipeline programs and recruitment strategies to increase the diversity of the R&D workforce. He serves as the GlaxoSmithKline representative on the steering committee for the Philadelphia STEM Equity Collective (PSEC). PSEC’s mission is to increase the number of underrepresented individuals in the Philadelphia workforce. Outside of work, Dr. Terrell is dedicated to the scientific community by serving on executive committees of several professional scientific organizations (i.e., American Chemical Society, NOBCChE). Dr. Terrell graduated salutatorian from Texas Southern University as a Fredrick Douglas honor scholar, earning a B.S degree in chemistry in 1995. He earned his Ph.D. in 2001 in organic chemistry from Michigan State. His graduate studies consisted of the total synthesis of the antiluekemic natural product amphidinolide A and the development of catalytic tin hydride reactions. Upon completion of his graduate studies at MSU, he continued his synthetic training with a 2-year postdoctoral stint at Stanford University.

Benjamin Wilfond, M.D., is an investigator at the Treuman Katz Center for Pediatric Bioethics and a pulmonologist at Seattle Children’s Hospital. He is a professor in the Division of Bioethics and Palliative Care and the Division of Pulmonary and Sleep Medicine in the Department of Pediatrics at the University of Washington School of Medicine. He founded and is former division chief of bioethics and palliative care and former director of the Treuman Katz Center for Pediatric Bioethics, the first such programs in the United States. He founded and is the former chair of the National Human Genome Research Institute’s intramural institutional review board and founded and is the former chair of the Clinical Research Ethics Consultation Collaborative, a national network to advance research bioethics consultation practice. Dr. Wilfond’s scholarship has focused on ethical and policy issues related to disabilities, genetics, and clinical research. His current scholarship relates to improving access for diverse

communities to advanced technologies including genomic sequencing, cellular therapeutics, and home mechanical ventilation as well as pragmatic research conducted within the context of health care delivery systems. Dr. Wilfond is the research ethics case co-editor of the American Journal of Bioethics and on the editorial boards of the Hastings Center Report, Ethics and Human Research, and the Journal of Genetic Counseling. He is a past president of the Association of Bioethics Program Directors, has been elected to the American Pediatric Society, and is a fellow at the Hastings Center. Dr. Wilfond attended Muhlenberg College, Rutgers University–New Jersey Medical School, and completed his postgraduate training at the University of Wisconsin. He has held faculty appointments at the University of Arizona, National Institutes of Health, and Johns Hopkins University.

SPEAKER AND PANELIST BIOSKETCHES

Rear Adm. Richardae Araojo, Pharm.D., serves as the associate commissioner for minority health and the director of the Office of Minority Health and Health Equity at the U.S. Food and Drug Administration (FDA). In this role, RDML Araojo provides leadership, oversight, and direction on minority health and health disparity matters for the agency. RDML Araojo previously served as the director of the Office of Medical Policy Initiatives in FDA’s Center for Drug Evaluation and Research (CDER), where she led a variety of broad-based medical and clinical policy initiatives to improve the science and efficiency of clinical trials and enhance professional and patient labeling. RDML Araojo joined FDA in 2003, where she held several positions in CDER. RDML Araojo received her doctor of pharmacy degree from Virginia Commonwealth University, completed a pharmacy practice residency at the University of Maryland, and earned a master’s degree in pharmacy regulation and policy from the University of Florida.

Murali Aravamudan, M.S., a serial entrepreneur, inventor, and engineer, is a founder and the chief executive officer of nference, a life sciences startup using artificial intelligence (AI) to unlock health care data through strategic partnerships with world-renowned health care systems, including the Mayo Clinic, Duke Health, and Vanderbilt University Medical Center. By offering real-time access to the richest multimodal data available, nference amplifies the impact and effectiveness of research and development and lifecycle management strategies across the biomedical and life sciences communities. Innovations at nference have led to the creation of affiliate ventures like Anumana, focusing on transforming cardiac care with AI solutions (ECG-AI); Pramana, revolutionizing digital pathology with a software-first approach to whole slide imaging; and Vimana,

focusing on diagnostic and therapeutic interventions in neuroscience. The parent and the affiliate companies have raised around $300 million in venture capital. Mr. Murali previously co-founded Veveo, focusing on efficient content discovery on devices, which was acquired by Tivo for over $75 million, and Winphoria Networks, a pioneer in mobile wireless soft switch and instant communications applications, acquired by Motorola for $200 million. He holds a master’s degree in electrical communication engineering from the Indian Institute of Science, Bengaluru, and has authored 137 U.S. patents with over 100 pending patents and academic publications in areas like machine learning, AI systems, computational biology, and clinical informatics.

Avery August, Ph.D., is a Howard Hughes Medical Institute professor, professor of immunology, deputy provost, and presidential advisor on diversity and equity at Cornell University. He received a B.S. in medical technology from California State University at Los Angeles, a Ph.D. in immunology from Cornell University’s Weill Cornell Graduate School of Medical Sciences, and a postdoctoral fellowship at the Rockefeller University from the National Science Foundation. After a brief stint in industry at the R.W. Johnson Pharmaceutical Research Institute as a scientist in drug discovery, he moved to The Pennsylvania State University, where he was a distinguished professor, after which he moved to Cornell as chair of the Department of Microbiology and Immunology in the College of Veterinary Medicine. His research focuses on understanding the immunological basis for the balance of inflammation and pathology in the lung during infectious and non-infectious insults. He is the chair of the steering committee for the Annual Biomedical Research Conference for Minoritized Scientists and has led the development of a number of funded programs aimed at diversifying science, technology, engineering, and mathematics at all levels. He is a fellow of the American Association for the Advancement of Science and the American Society for Microbiology, and he has won a number of awards for his research and for his work in diversifying science. He has served on a number of national and international government and non-profit committees and is currently on the board of trustees for the New York Blood Center and The Guthrie Clinic.

Marie A. Bernard, M.D., is the National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD). As the COSWD, she leads NIH thought regarding the science of scientific workforce diversity, assuring that the full range of talent is accessed to promote scientific creativity and innovation. Dr. Bernard co-led the development and is co-leading the implementation of the fiscal years 2023–2027 NIH-wide Strategic Plan for Diversity, Equity, Inclusion, and Accessibility (DEIA). She also

cochairs the NIH Advisory Committee to the Director Working Group on Diversity, the NIH Steering Committee Working Group on DEIA, and the NIH UNITE initiative to identify and address any structural racism that may exist within NIH and throughout the biomedical and behavioral workforce. Prior to being selected as the COSWD, Dr. Bernard served as the deputy director of the National Institute on Aging, following a productive research and leadership career as an academic geriatrician.

Amanda Bryant-Friedrich, Ph.D., M.S., is the dean of the graduate school and a professor of pharmaceutical sciences at Wayne State University. Her early training was in organic chemistry at North Carolina Central University and Duke University. She obtained her doctorate in pharmaceutical chemistry at the Ruprecht-Karls Universität Heidelberg in Germany followed by postdoctoral training at the Universität Basel in Switzerland. She held the positions of assistant and associate professor at Oakland University in Rochester, Michigan, before moving to the University of Toledo. She is a fellow of the American Association for the Advancement of Science and the American Chemical Society (ACS) and an academic leadership fellow of the American Association of Colleges of Pharmacy. She is the immediate past chair of the ACS Division of Medicinal Chemistry and past chair of the ACS Multidisciplinary Planning Group and has served several roles in the ACS Division of Chemical Toxicology, including program chair. She also held leadership positions in the Radiation Research Society. Her research interests center around the development of tools to investigate processes and treat diseases related to nucleic acids and their metabolism.

Blayne Cutler, M.D., Ph.D., is the president and chief executive officer of Heluna Health, a national nonprofit leader providing program and support services to optimize population health. She is a physician trained in infectious disease and epidemiology. Prior to joining Heluna Health in 2014, Dr. Cutler served as New York City’s assistant commissioner for HIV prevention and control under Mayors Michael Bloomberg and Bill DiBlasio and as the city’s director of HIV prevention from 2007 to 2013. She has published widely on topics related to HIV, epidemiology, history and public health. Dr. Cutler has lectured at universities around the world and has assisted in the scale-up of HIV treatment and care in Africa. She received her medical degree at the University of Pennsylvania and completed her residency training at Brown University and her infectious diseases fellowship at Columbia University. Dr. Cutler also has a love of the humanities: she holds a doctorate in history from Yale and worked as a journalist prior to becoming a physician.

Linda L. Demer, M.D., Ph.D., is a professor in the departments of medicine, physiology, and bioengineering at the University of California, Los Angeles (UCLA), and vice chair of the Department of Medicine. She received her M.D. concurrently with a Ph.D. in bioengineering at the Johns Hopkins School of Medicine. Her research group pioneered the field of vascular calcification and made paradigm-shifting discoveries showing that artery wall cells transform into bone cells in cardiovascular calcification. Dr. Demer has served as associate editor and editorial board member for multiple cardiovascular journals, and she served as president of the Association of Professors of Cardiology, the Western Society for Clinical Investigation, the Association of University Cardiologists, and the North American Vascular Biology Organization. She founded and has directed for 30 years the unique UCLA Specialty Training and Advanced Research (STAR) program, which provides Ph.D. training for physicians at the latest stages of subspecialty training, with over 235 graduates to date. She also serves as co-director for physician scientist career development in the dean’s office for the David Geffen School of Medicine at UCLA.

Tonya Fancher, M.D., M.P.H., is the vice chair for workforce diversity, associate dean of workforce innovation, and professor and interim head of general internal medicine at the University of California (UC), Davis, School of Medicine. As director of the Center for a Diverse Healthcare Workforce, she has worked to address physician shortages with grants from the Health Resources and Services Administration (HRSA) and the American Medical Association and with partnerships with regional employers. She has created medical school pathways to improve care for medically underserved communities, a community college to medical school pathway, and helped UC Davis become the third-most diverse medical school in the United States. Dr. Fancher serves on the Accreditation Council for Graduate Medical Education’s DEI Advisory Committee and HRSA’s Advisory Committee on Training in Primary Care Medicine and Dentistry. Dr. Fancher graduated from Cornell University (classics and biology) and completed medical school and residency at New York University and Bellevue Hospital. Her scholarly work focuses on challenges and solutions to inequities in medical education.

Marwan Fathallah, M.S., M.B.A., has three decades of global life science leadership experience in pharmaceutical, medical device, diagnostic, and biotechnology product research and development and has served as president and global chief executive of DIA since January 2023. Prior to joining DIA, Mr. Fathallah was the operating officer and executive vice president at Ortho Clinical Diagnostics, accountable for operations, post-market product science and engineering, and regulatory, quality, medical,

clinical, scientific affairs, and process excellence. Before joining Ortho, he held executive and senior leadership roles in research and development, operations, and regulatory medical and clinical affairs at Avantor, Danaher, Pfizer, Hospira, and Abbott Laboratories. Mr. Fathallah holds master’s and bachelor of science degrees in mechanical engineering from the University of Wisconsin–Madison and an M.B.A. from the Kellogg School of Management at Northwestern University.

Cynthia Fuhrmann, Ph.D., directs the Professional Development Hub and is associate professor of the RNA therapeutics unit at the University of Massachusetts Chan Medical School. Dr. Fuhrmann’s work sits at the nexus of practice, scholarship, and policy to advance the professional development of early-career scientists. She has 18 years’ experience founding professional development programs for graduate students, postdoctoral scholars, and faculty, with educational innovations funded by the the National Institutes of Health, National Science Foundation (NSF), and Burroughs Wellcome Fund and honored by two awards from the Association of American Medical Colleges. She is a pioneer of individual development plans (IDPs) in graduate/postdoctoral education, including co-developing myIDP (an online tool used worldwide), integrating career planning into curricula, and co-developing survey instruments for studying IDP use. Dr. Fuhrmann’s national service includes the Roundtable on Mentorship, Well-being, and Professional Development at the National Academies of Sciences, Engineering, and Medicine, advising the Council of Graduate School’s NSF Innovations in Graduate Education Hub, and serving on grant review boards and numerous training advisory boards. She leads Professional Development Hub, a cross-stakeholder national initiative to advance equitable, evidence-based practices in science, technology, engineering, and mathematics Ph.D. professional development. She earned her Ph.D. in biochemistry and molecular biology at the University of California, San Francisco, and B.S. in chemistry at University of California, Davis.

Anne Granger, Ph.D., is the head of the postdoctoral program and a member of the Academic Partnerships and External Innovation team at Novartis Biomedical Research. The Biomedical Research Postdoctoral Program, which counts over 550 alumni, currently hosts 70 fellows in four campuses across the United States and Switzerland. Dr. Granger designed and launched the Novartis Innovation Fellowship, a training program for aspiring drug hunters complementing the existing academically oriented program. Prior to joining Novartis Biomedical Research, Dr. Granger was a senior scientific editor for the Cell Press journal Cell Metabolism for 7 years. She received her Ph.D. in molecular and cellular biology from the

University Pierre and Marie Curie (Paris, France) and was a postdoctoral fellow at the University of Pennsylvania and the Childrens’ Hospital of Philadelphia, where she studied cardiovascular biology and diabetes.

Adrian Hernandez, M.D., M.H.S., is the executive director of the Duke Clinical Research Institute and vice dean of the Duke University School of Medicine. He is a cardiologist who aims to improve health by accelerating clinical evidence through outcomes research, clinical trials, comparative effectiveness, and health policy. He has led multiple large-scale patient-centered research programs, registries, and clinical trials across multiple health conditions, including the National Institutes of Health’s Health System Collaboratory and the Patient-Centered Outcomes Research Institute–funded PCORnet^®. He is an elected member of the American Society for Clinical Investigation and the Association of American Physicians and serves on the board of directors of the Reagan–Udall Foundation.

Stephanie A. Kraft, J.D., is an assistant professor in the Division of Bioethics and Palliative Care, Department of Pediatrics at the University of Washington School of Medicine, as well as a principal investigator and the director of research at the Truman Katz Center for Pediatric Bioethics and Palliative Care at Seattle Children’s Research Institute. Professor Kraft is a bioethics scholar with a focus on ethics and equity in clinical research and emerging biomedical technologies. Her research aims to incorporate the voices of research participants, patients, and community members, particularly those of marginalized and minoritized groups, into research practices and technology development to ensure biomedical advances reduce, rather than exacerbate, health disparities. Her work is currently funded by the National Human Genome Research Institute and the National Center for Advancing Translational Sciences.

Mary Jo Lamberti, Ph.D., is a research associate professor at Tufts University Medical School and director of sponsored research at the Tufts Center for the Study of Drug Development. She has extensive experience in benchmarking drug development operating practices. Her research focuses on a variety of areas, including clinical research workforce issues, investigative site initiation and management, and patient recruitment and retention in clinical trials. In addition, she has examined the impact of technology and remote work on clinical research professionals. Through her work on health disparities among underrepresented populations, she has focused on identifying strategies that create clinical trial awareness and education and approaches to improving access among diverse populations. She has been a frequent speaker at global industry conferences and has published extensively. She holds a B.A. from Wellesley College and a Ph.D. from Boston University.

Susan P. Landis serves as the executive director for the Association of Clinical Research Professionals (ACRP). With more than 14,000 members, ACRP is the only nonprofit organization solely dedicated to representing, supporting, and advocating for clinical research professionals. ACRP’s mission is to ensure excellence in clinical research. Prior to joining the association, Ms. Landis led strategic engagement and marketing communications for the Duke Clinical Research Institute (DCRI). While at Duke, she established and led the DCRI research communications and engagement group and created ResearchTogether™, a model for championing patient engagement at every phase in clinical research trials and studies. Ms. Landis also served as a team member on commercial-funded interventional and outcome studies and several large government-funded trials, including the Environmental Influences on Child Health Outcomes program, the ABC Science Collaborative, and RADx-UP. Prior to joining Duke, Ms. Landis worked at Quintiles (now IQVIA) as an executive for the company’s Patient Engagement division. She also managed the company’s branding initiatives and thought leadership program and served as a corporate communications business partner for the company’s business units which represented more than $5 billion and 30,000 employees.

Bill Lindstaedt, M.S., has been helping scientists and engineers launch successful careers for 30 years. From 2001 to 2023, he supported the career development needs of Ph.D. students, postdocs, and their faculty mentors at the University of California, San Francisco (UCSF). In his career counseling practice, he developed particular expertise working with biomedical scientists as they transition from academic positions to careers in the biotech/pharma sector. While at UCSF, Mr. Lindstaedt co-authored Science’s “myIDP,” a web-based career development tool which has been used by more than 300,000 scientists and is recommended by dozens of graduate and postdoctoral programs around the country. Recently retired from UCSF, he now serves as co-investigator on a National Institutes of Health–funded initiative to build science, technology, engineering, and mathematics Ph.D. professional development resources across institutions. Additionally, he serves as a contracted career consultant with the Office of Academic Programs at St. Jude Children’s Research Hospital and with Emory University’s Office of Postdoctoral Education.

Tracie Locklear, Ph.D., is the director of the Clinical Research Sciences Program at North Carolina Central University (NCCU). The program was established in 2019 to build a clinical research workforce of the future with a strong focus on workforce diversity, health equity, and community engagement. She serves as the NCCU lead for the workforce development core under the Duke-NCCU Clinical and Translational Science Award and

a member of Consortium of Academic Programs in Clinical Research. Dr. Locklear is a community-based researcher focused on improving health outcomes for rural communities, historically marginalized communities in particular.

Arch G. Mainous III, Ph.D., is a professor and the vice chair for research in the Department of Community Health and Family Medicine and a professor in the Department of Health Services Research, Management, and Policy at the University of Florida. He is an internationally recognized leader in primary care research, with more than 450 peer-reviewed publications. His work has been cited more than 29,500 times with an H index of 84. Dr. Mainous has been active in developing the health care workforce. He has received the Distinguished Research Mentor award and the Maurice Wood Award for Lifetime Contribution to Primary Care Research from the North American Primary Care Research Group. He has served as a special advisor for health and health care to the Prime Minister of Haiti. Dr. Mainous currently serves as the deputy editor of the journal Family Medicine and the specialty chief editor of Frontiers in Medicine: Family Medicine and Primary Care.

Kenneth Maynard, Ph.D., FAHA, is the director of global program team effectiveness at Takeda Pharmaceuticals. He previously led global drug discovery and clinical development teams in neuroscience, external innovation, portfolio strategy, and pharmacovigilance. Before pharma, Dr. Maynard was an academic stroke neuroscientist researcher and assistant professor (neurosurgery) at Massachusetts General Hospital and Harvard Medical School. He earned his B.Sc., M.Sc., and Ph.D. degrees in neurobiology at University College, London. He is a fellow of the American Heart Association and serves on several advisory boards, including for the Society for Neuroscience Council, Worcester Polytechnic Institute’s College of Arts and Sciences, the National Institute of Nervous Disorders and Stroke, and the University of Seattle’s Broadening the Representation of Academic Investigators in NeuroScience. He previously served on the National Institutes of Health Director’s Program on Broadening Experiences in Scientific Training and the National Academies of Sciences Committee on the Next Generation of Biomedical and Behavioral Sciences Researchers.

Joseph P. Menetski, Ph.D., has been at the Foundation for the National Institutes of Health (FNIH) as senior vice president of science partnerships and chief translational science officer since 2016. In this role he leads a group to identify, develop, and execute multi-stakeholder medical research partnerships in the areas of cancer, neuroscience, inflamma-

tion and immunity, metabolic disorders, and rare diseases. FNIH provides a forum that allows all project stakeholders—from NIH, academia, pharmaceutical industry, and patient advocacy and professional organizations—the opportunity to contribute directly to the direction and governance of these projects. Prior to joining to FNIH, he worked at Merck, where he was involved in initiating the osteoarthritis new targets and biomarker program, biomarker discovery using molecular profiling, scientific knowledge discovery and management, and competitive intelligence. Dr. Menetski has also worked at Pfizer (Parke-Davis) where he established a discovery research program in cellular inflammation mechanisms. He received his Ph.D. from Northwestern University Medical School in Chicago.

Susan C. Monarez, Ph.D., is a globally recognized leader with over 20 years of experience in health innovation. She currently serves as the deputy director at the Advanced Research Projects Agency for Health (ARPA-H). ARPA-H supports the development of high-impact research to drive biomedical and health breakthroughs to deliver transformative, sustainable, and equitable health solutions for everyone. Prior to this position, Dr. Monarez was at the Health Resources and Services Administration, the largest funder of safety-net health programs in the Department of Health and Human Services (HHS). Dr. Monarez has also served at the White House as the Assistant Director for National Health Security and International Affairs in the Office of Science and Technology Policy and as the director of medical preparedness policy on the National Security Council. In both White House roles, she led multiple efforts to enhance the nation’s biomedical innovation capabilities. Dr. Monarez has led the development of several Presidential-level national strategies, action plans, and policy directives related to domestic and global health. Prior to the White House, Dr. Monarez served in leadership positions at the Homeland Security Advanced Research Projects Agency (HSARPA) within the Department of Homeland Security and the Biomedical Advanced Research Projects Agency within HHS. In addition to leadership roles within the federal government, Dr. Monarez has been called upon to serve on numerous advisory panels to include at the National Academies of Science, the National Science Advisory Board for Biosecurity, and the Federal Experts Science Advisory Panel. Dr. Monarez has also served as the U.S. representative on several international cooperative initiatives including with the European Union, Canada, France, the Netherlands, and the United Kingdom in bilateral and multilateral engagements. Dr. Monarez was an American Association for the Advancement of Science Science and Technology Policy fellow and a research scientist in microbi-

ology and immunology at the University of Wisconsin and at the Stanford University School of Medicine.

Keith Norris, M.D., Ph.D., is an internationally recognized clinician scientist and health policy leader who has been instrumental in shaping clinical practice guidelines for chronic kidney disease, developing policy initiatives to address health disparities, and increasing diversity in clinical trials and in the biomedical sciences. He is a distinguished professor and executive vice chair for equity, diversity, and inclusion for the University of California, Los Angeles (UCLA) Department of Medicine and co-director of the UCLA Clinical and Translational Science Institute Community Engagement Research Program. Dr. Norris was one of 20 site principal investigators (PIs) for the multi-site African American Study of Kidney Disease and Hypertension (AASK) and the AASK Cohort Study, funded by the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases, which was the largest comparative drug intervention trial focusing on renal outcomes conducted in African Americans. He has conducted NIH- and U.S. Food and Drug Administration–related trials and community-partnered research for 40 years. He serves as a PI or multi-PI for six NIH research and training grants focused on addressing health disparities and increasing biomedical workforce diversity.

Elizabeth O. Ofili, M.D., M.P.H., FACC, is a professor of medicine at the Morehouse School of Medicine and a practicing cardiologist with Morehouse Healthcare in Atlanta, Georgia. A national and internationally recognized clinician scientist with particular focus on cardiovascular disparities and women’s health, Dr. Ofili has helped to raise over $200 million to fund pioneering research and training infrastructure at the Morehouse School of Medicine. She leads multi-institutional regional and national networks funded by the National Institutes of Health (NIH) to address diversity and inclusion in the biomedical workforce as well as community engagement to ensure participation of underrepresented populations in NIH-, foundation-, and industry-sponsored research, including serving as principal investigator of the statewide Georgia Clinical and Translational Science Alliance, at Emory University, Morehouse School of Medicine, Georgia Institute of Technology, and the University of Georgia; contact principal investigator of the Research Centers in Minority Institutions (RCMI) Coordinating Center for 22 NIH-funded RCMI to support investigator development, community engagement, and evaluation; principal investigator of the National Research Mentoring Network; and contact principal investigator of the Coordination and Evaluation Center for

the NIH Faculty Institutional Recruitment for Sustainable Transformation Program for Inclusive Excellence. She has received over 50 national awards, including “Changing the Face of Medicine: The Rise of America’s Women Physicians” Exhibit at the National Library of Medicine. She is an elected member of the National Academy of Medicine.

Priscilla Pemu, M.D., is a doctor specializing in the care of adults with complex medical problems under treatment in clinic and hospital settings. She also trains medical students and new doctors specializing in internal medicine. As a physician–scientist, she leads research funded with grants from the National Institutes of Health and the American Heart Association, informed by her daily experiences with patients. She is continuously inspired to investigate the best ways to improve the long-term health of patients living with chronic illnesses (cancer, diabetes, etc.). Dr. Pemu is currently a professor of clinical medicine, the medical director of the Clinical Research Center, and vice chair for research in the Department of Medicine at Morehouse School of Medicine (MSM) in Atlanta, Georgia. As part of a team at MSM, she developed a system and method for providing care to patients with chronic illnesses that empowers patients to change their behaviors relevant to their health; this is achieved by efforts to improve patient’s knowledge and provide support for their goal setting and accountability so they may sustain their lifestyle changes. Dr. Pemu continues to explore and implement key patient-centered concepts that are relevant to improving health outcomes and transforming health care. She’s passionate about speaking to audiences such as health care managers and funders, affected patient groups, health coaches, and other scientists who are interested in achieving that goal as well.

Tyrone Quarterman, M.P.H., is the senior manager of health equity and diversity at Myriad Genetics, Inc. Within Myriad he is responsible for health equity and access; diversity, equity, and inclusion; university affairs and relations; learning and development; and charitable giving. Mr. Quarterman has an extensive background ranging from equity and access in clinical and non-clinical research to addressing community needs and health disparities in urban and rural environments. An avid proponent of health equity and social justice in health care, Mr. Quarterman prides himself on continuing to advance the mission of equal access for all within health care in the pharmaceutical and biotech space. He is known for a variety of discussions and lectures on health equity, addressing disparities, and health inequalities.

Nina F. Schor, M.D., Ph.D., is currently the deputy director for intramural research at the National Institutes of Health (NIH), a post she has held since August 2022. Before coming to NIH, Dr. Schor spent 20 years on faculty at the University of Pittsburgh, ultimately becoming the Carol Ann Craumer Professor of Pediatric Research, chief of the Division of Child Neurology in the Department of Pediatrics, and associate dean for medical student research at the medical school. In 2006, Dr. Schor became the William H. Eilinger Chair of the Department of Pediatrics and pediatrician-in-chief of the Golisano Children’s Hospital at the University of Rochester, posts she held until January 2018, when she became the deputy director of the National Institute of Neurological Disorders and Stroke (NINDS). For 27 years in academia, her research on neural crest development and neoplasia was continuously funded by NIH. At NINDS, she led the Division of Intramural Research and the Ultra-Rare GENe-targeted Therapies (URGenT) Network and strategic planning and career development programs. She also continues to serve as a neurology director for the American Board of Psychiatry and Neurology.

Ramita Tandon, M.P.H., is the chief clinical trials officer at Walgreens and responsible for leading and driving growth for the company’s new clinical trials business. In her role, Ms. Tandon works across the health care and life sciences industries to enable next-generation clinical trials so that breakthrough treatments reach patients faster. Ms. Tandon’s motto is “talk less and do more.” Every day, she lives this out by showing and setting industry standards on addressing access and health equity. She and her team are working to make clinical research an inherent care option across this nation when the standard of therapy is not a viable option.

Ms. Tandon brings more than 25 years of leadership and operational experience across a portfolio of industry-leading businesses and services in real-world evidence and patient-centered health outcomes. Prior to joining Walgreens, she served as the chief operating officer at Trio Health, and prior to that she was the executive vice president, commercialization and outcomes, at ICON. She was recently named to the Center for Healthcare Innovation’s board of directors. As a transformational leader, Ms. Tandon is passionate in her belief that a best-in-class operating model employing insights and innovation can deliver gains in operations and forge stronger connections with all stakeholders, including biopharmaceutical companies, health care systems, and payers. Ms. Tandon was recently named to Mass Market Retailers’ 2023 Most Influential Women, Drug Store News’ Top Women in Health, Wellness & Beauty class of 2022 for Business Excellence, and Fierce Healthcare’s 2022 Women of Influence, and she was listed in the PharmaVOICE 100 in 2023 and 2018.

On top of her individual accolades, under Ms. Tandon’s leadership the Walgreens clinical trials business was nominated at the 2022 Prix Galien USA in the category for “Incubators, Accelerators and Equity,” commended in the 2022 Clinical Trials Arena Excellence Awards, and was just shortlisted in the PRWeek Healthcare Awards 2023 “Best Healthcare Product Launch” category. Ms. Tandon is an internationally recognized speaker and author whose focus is on how to bridge the gap between commercial and clinical development. She is a graduate of the University of Michigan and the Boston University School of Public Health.

Ann Taylor, M.D., is currently the co-chair of the Forum on Drug Discovery, Development, and Translation of the National Academies of Sciences, Engineering, and Medicine. Her career has spanned academic medicine, pharmaceutical development, and biotechnology. She currently is on the board of several biotechnology companies. Her most recent pharmaceutical company roles included chief medical officer at AstraZeneca, head of clinical biologics at Medimmune, head of the program office at Novartis Institutes for Biological Research (NIBR), acting head of cardiovascular and metabolic research and head of translation medicine for metabolism at NIBR. Prior to joining Novartis, Dr. Taylor worked as an early clinician at Pfizer Global Research and Development. She received her undergraduate degree from the University of California, San Diego, and her M.D. from Harvard Medical School. She trained in internal medicine and endocrinology and metabolism at Massachusetts General Hospital, before joining the faculty there. She is passionate about improving representation in clinical trials.

Perdita Taylor-Zapata, M.D., is a pediatrician from the Washington, D.C., metropolitan area. She attended D.C. public schools and graduated from Howard University for both college and medical school. After completing her pediatric residency at the Children’s National Medical Center, she joined the National Institutes of Health clinical center as a staff physician in the pediatric HIV program. In 2004, Dr. Taylor-Zapata joined the National Institute of Child Health and Human Development, where she is currently responsible for the oversight and implementation of a pediatric drug development research program called the Best Pharmaceuticals for Children Act Clinical Program. She also manages and maintains a portfolio of grants in the area of pharmacoepidemiology and pharmacovigilance in pediatric research.

Julia (Julie) Tierney, J.D., is the chief of staff of the U. S. Food and Drug Administration (FDA), overseeing the daily management of the agency and leading agency activities on major initiatives. In this role, she provides strategic direction to senior leadership to advance FDA’s policy priorities and works closely with the leadership of all FDA product centers and field operations to support their implementation of agency policies. She also serves as the acting commissioner’s direct liaison to other executive agencies and organizations and engages across government on critical public health initiatives. Ms. Tierney also plays a key role in legislative engagement, communications and stakeholder outreach. Most recently, Ms. Tierney was the chief of staff for FDA’s Center for Biologics Evaluation and Research (CBER). In that capacity, she served as the principal advisor to CBER director Peter Marks, M.D., and facilitated planning and implementation of CBER priorities. Ms. Tierney first joined CBER in early 2017 as a senior policy advisor for strategic planning and legislation. From 2015 to 2016, Ms. Tierney was FDA’s detailee to the U.S. Senate Health, Education, Labor, and Pensions Committee as a senior health policy advisor. She joined FDA in 2008 as an associate chief counsel for drugs in FDA’s Office of Chief Counsel, providing ongoing legal counsel to FDA leadership and program staff on drug and biologic-related legal issues. Prior to working at FDA, Ms. Tierney practiced food and drug law at private law firms. She received her J.D. from Georgetown University Law Center and her undergraduate degree in biology and history from Johns Hopkins University.

Katherine R. Tuttle, M.D., FASN, FACP, FNKF, is the executive director for research at Providence Inland Northwest Health, a regional principal investigator of the Institute of Translational Health Sciences, and a professor of medicine at the University of Washington. She oversees a regional network of 17 clinical research centers and chairs the research regional executive council for the University of Washington. Dr. Tuttle’s major research interests are in diabetes and chronic kidney disease. She has published over 320 peer-reviewed articles, including an early landmark study elucidating physiological principles underlying kidney hemodynamics in humans with diabetes. This led to a number of studies that laid a foundation for new therapeutic targets in clinical trials. Her work has helped establish SGLT2 inhibition as the most impactful therapy to date to reduce risks of kidney failure, cardiovascular events, and death in persons with diabetes. She also leads the Center for Kidney Disease Research, Education and Hope registry of real-world data from nearly 4 million health system patients. She has chaired numerous working groups and committees for the National Institutes of Health, the American Society of Nephrology, the International Society of Nephrology, Kidney Disease

Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards, including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology.

John (Wig) Wigneswaran, M.D., M.B.A., is the chief medical officer at Walmart, where he arrived after working in the pharmaceuticals, medical device, health services, and pharmacy benefit manager (PBM) industries. He joined Walmart from Cigna where he served as chief medical officer for Express Scripts, helping lead clinical program development and business development in the commercial, health plan, and regulated market segments. Prior to this he was chief medical officer at DaVita Rx, at that time the country’s largest renal PBM leading specialty clinical programs; vice president of market development at Fresenius Medical Care, growing several business lines outside of chronic dialysis and leading supply chain transformation; nephrology lead of medical affairs at Johnson & Johnson (Scios®); and chief medical officer for CHF Solutions/Gambro. He has over a decade of clinical experience as a practicing nephrologist and serves as a renal fellowship preceptor in the Division of Nephrology at Rhode Island Hospital/Brown University. Dr. Wig completed his undergraduate studies at Cornell University, medical school at Tufts University School of Medicine, M.B.A. at the Massachusetts Institute of Technology Sloan School of Management, and internal medicine residency and nephrology fellowship training at New York Hospital/Cornell University and Rhode Island Hospital/Brown University. Dr. Wig currently serves as a board member for the National Kidney Foundation.

Robert A. Winn, M.D., serves as a member of the external advisory board for the Indiana University Simon Comprehensive Cancer Center, the director of the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC), and a professor in the VCU Department of Internal Medicine, Division of Pulmonary Disease and Critical Care Medicine. As MCC director, Dr. Winn is ultimately responsible for setting the vision, scientific and clinical goals, and strategic direction of the center. He is in charge of identifying and providing the resources needed for strategic plan implementation and monitoring center progress. Dr. Winn is also a member of the Cancer Prevention and Control Program. As a pulmonologist and physician-scientist, his research centers on lung cancer and health disparities. Dr. Winn has focused on developing novel in vitro and in vivo models to study the translational aspects of the role that various signaling pathways (e.g. WNTs, PRMT, KS RP) play in lung cancer, which has resulted in a number of peer-reviewed journal publications. He has been awarded several National Institutes of Health (NIH) and Depart-

ment of Veterans Affairs grants and has a long history of developing productive collaborations with other successful R01-funded researchers. Dr. Winn has served as the principal investigator on several team-science community-based projects funded by the National Institute on Minority Heath and Health Disparities and the National Cancer Institute, including the All of Us Research Program, an NIH precision medicine initiative. He is committed to developing methods to eliminate health disparities and will continue to focus his efforts on underserved patient populations to improve health care delivery and ensure equal access to cutting-edge medical treatments.

Anne Zajicek, M.D., Pharm.D., is a board-certified pediatrician and pediatric clinical pharmacologist and the program director of the Office of Clinical Research Education and Collaboration Outreach (OCRECO) at the National Institutes of Health (NIH). Dr. Zajicek develops and oversees online clinical pharmacology and clinical research training programs and strategic partnerships with the extramural community. Dr. Zajicek earned her bachelor’s degree in pharmacy from Duquesne University and a Pharm.D. from the State University of New York at Buffalo; completed a fellowship at St. Jude Children’s Research Hospital; and served as faculty at the University of Colorado School of Pharmacy and as a clinical pharmacist at National Jewish Health. In 1995 Dr. Zajicek earned her medical degree at the University of Pittsburgh and completed her residency in pediatrics at the Children’s Hospital of Pittsburgh. She practiced primary care pediatrics and then continued her training as a pediatric clinical pharmacology fellow at Stanford University. She subsequently joined the U.S. Food and Drug Administration as a clinical pharmacology reviewer. In 2003 she joined the Eunice Kennedy Shriver National Institute of Child Health and Human Development and was appointed chief of the Obstetric and Pediatric Pharmacology and Therapeutics Branch in 2010. In 2017, Dr. Zajicek moved to the NIH OCRECO.

STAFF BIOSKETCHES

Carolyn K. Shore, Ph.D., is a senior program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. She is staff director of the Forum on Drug Discovery, Development, and Translation. Before joining the National Academies, Dr. Shore was an officer on Pew’s antibiotic resistance project, leading work on research and policies to spur the discovery and development of urgently needed antibacterial therapies. She previously served as a foreign affairs officer at the U.S. Department of State, where she led an

initiative on open data and innovation-based solutions to global challenges. She also served as the State Department’s representative to intergovernmental organizations focusing on food safety, plant and animal health, biosecurity, and agricultural trade policy. Previously, Dr. Shore was an American Society for Microbiology congressional fellow, working on science-based policy related to antibiotic stewardship and other public health issues. She holds a doctoral degree in microbiology and molecular genetics from Harvard University. As a graduate student, she studied antimalarial drug resistance in Senegal and worked jointly between the Medicines for Malaria Venture, Genzyme Corporation, and the Broad Institute of Harvard and the Massachusetts Institute of Technology to discover new antimalarial compounds. Dr. Shore was awarded a Fulbright Fellowship for work at the University of Queensland in Brisbane, Australia, and a National Institutes of Health Training Grant for postdoctoral work at the University of Iowa.

Kyle Cavagnini, Ph.D., is an associate program officer with the Board on Health Sciences Policy. They currently staff the Forum on Drug Discovery, Development, and Translation, where their portfolio includes opioid disposal and drug research and development for chronic diseases. Dr. Cavagnini previously worked with the National Academies Institute for Laboratory Animal Research, where they supported the Standing Committee for the Care and Use of Animals in Research and workshop committees engaged in the One Health field. Prior to joining the National Academies, Dr. Cavagnini completed a science policy fellowship with the Federation of American Societies for Experimental Biology and was a Fulbright Fellow in the Department of Biomedicine at the University of Bergen, Norway. They earned their Ph.D. in biological chemistry from the Johns Hopkins University School of Medicine, where their doctoral research focused on genomic contributions to metabolic sensing in the liver and other tissues. They received undergraduate degrees in biochemistry and philosophy from the University of North Carolina at Asheville.

Brittany Hsiao, M.S., is an associate program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. She currently staffs the Forum on Drug Discovery, Development, and Translation. She attended the University of Virginia where she graduated with a bachelor of arts in public health and a minor in Spanish. Throughout her undergraduate education, she engaged in public health research and clinical trials research. Due to her passion in biology and medicine, she later received her master of science in biomedical sciences from Eastern Virginia Medical School. Prior to joining the National Academies, she worked in a variety of clinical settings, including

the University of Virginia’s Fontaine Research Center, a private internal medicine practice, an ophthalmology clinic specializing in macula and retina, and INOVA Fairfax Hospital.

Noah Ontjes, M.A., is an associate program officer with the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. He currently staffs the Forum on Drug Discovery, Development, and Translation, co-leading projects on engaging community practices in clinical trials and preparing the future workforce in drug research and development. He attended Wake Forest University where he graduated with a bachelor of science in biology and a triple minor in bioethics, chemistry, and psychology. His interest in the multiple factors that influence one’s health paired with his love of different perspectives led him to pursue a master of arts in bioethics at Wake Forest University. During graduate school, he successfully defended his thesis on the reasonable person standard of disclosure in genetic research as well as collaborated on a published paper concerning the ethical considerations of electroconvulsive therapy on incapacitated patients. Overall, he likes to categorize himself as someone who is intellectually curious.

Melvin Joppy is a senior program assistant on the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine. He previously served as a program assistant at the Department of Energy (DOE) in the Office of Basic Energy Sciences. Prior to DOE, Mr. Joppy served as the committee manager for the Presidential Advisory Council on HIV/AIDS within the U.S. Department of Health and Human Services. He received his B.S. in communications from Bowie State University.

This page intentionally left blank.